Not exact matches
Quest Diagnostics Inc. said it would
sell testing for the
genes later this year.
By invalidating key parts of Myriad's patents, the court has removed a bar that prevented labs using new technology from developing and
selling broader one - time
tests that search for all known cancer risks, including the BRCA
genes, geneticists said.
In 2006 Pfizer started early human
testing on one of these new, targeted drugs called crizotinib (now
sold as Xalkori), concentrating on a mutation of a
gene called MET, implicated in several cancers, including esophageal and stomach cancer.
Charles Zukoski, Urbana - Champaign's vice chancellor of research, said that the school notified FDA of its intention to
test the piglets and
sell those that
tested negative for foreign
genes to a livestock dealer.
Instead, they helped Myriad Genetics, the company that studied those tissues, to establish broad
gene patents and achieve large profits by
selling tests that many donor families could not afford.